Stock CALTX CALLIDITAS THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Real-time Estimate Cboe Europe
Other stock markets
 05:06:17 2024-05-28 am EDT 		5-day change 1st Jan Change
201.9 SEK +77.73% Intraday chart for Calliditas Therapeutics AB +74.14% +58.93%
May. 24 HC Wainwright Cuts Calliditas Therapeutics Price Target to $45 From $50, Maintains Buy Rating MT
May. 23 Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
European shares waver as euro zone consumers lower inflation expectation
Calliditas Therapeutics Receives SEK11.2 Billion Takeover Offer from Japan’s Asahi Kasei
Asahi Kasei to buy Swedish drugmaker Calliditas for $1.1 billion
L'inflation revient doucement dans le jeu
En Direct des Marchés : Stellantis, Edenred, Klépierre, Quadient, ABN Amro, Calliditas, Metex...
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading
Calliditas Therapeutics AB Reaffirms Earnings Guidance for the Year Ending December 31, 2024
Calliditas Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading
Calliditas Therapeutics Partner Offers Nefecon in China; Shares Rise
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading
Calliditas Therapeutics AB Announces Positive Topline Results of Phase 2 Head and Neck Cancer Trial with Lead NOX Inhibitor Candidate, Setanaxib
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading
Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings
Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CALTX Stock
  4. News Calliditas Therapeutics AB
  5. Other languages